Luminex Submits xTAG® CYP2C19 Kit to FDA for Review<br />
<br />
AUSTIN, Texas – Luminex Corporation (NASDAQ: LMNX) today announced it has received U.S. FDA and European clearance for a new version of xTAG CYP2D6 Kit. Additionally the company has submitted xTAG 2C19 Kit to FDA for review. Luminex is advancing its pharmacogenetic initiative for improved patient care.<br />
<br />
"Test results that inform a physician on how a patient may react to a particular therapeutic are vital to ...This story is related to the following:Laboratory Equipment & Supplies